Aims: Previously, detection of ANO5 protein has been complicated by unspecific antibodies, most of which have not identified the correct protein. The aims of the study were to specify ANO5 protein expression in human skeletal muscle, and to investigate if the ANO5 protein levels are affected by different ANO5 mutations in anoctaminopathy patients. Methods: Four different antibodies were tested for ANO5 specificity. A sample preparation method compatible with membrane proteins, combined with tissue fractionation was used to determine ANO5 expression in cell cultures expressing ANO5, in normal muscles and eight patient biopsies with six different ANO5 mutations in homozygous or compound heterozygous states, and in other dystrophies. Results: Only one specific monoclonal N-terminal ANO5 antibody was efficient in detecting the protein, showing that ANO5 is expressed as a single 107 kD polypeptide in human skeletal muscle. The truncating mutations c.191dupA and c.1261C>T were found to abolish ANO5 expression, whereas the studied point mutations had variable effects; however, all the ANO5 mutations resulted in clearly reduced ANO5 expression in the patient muscle membrane fraction. Attempts to detect ANO5 using immunohistochemistry were not yet successful. Conclusions: The data presented here indicate that the ANO5 protein expression is decreased in ANO5-mutated muscular dystrophy and that most of the nontruncating pathogenic ANO5 mutations likely destabilize the protein and cause its degradation. The method described here allows direct analysis of human ANO5 protein, which can be used in diagnostics, for evaluating the pathogenicity of the potentially harmful ANO5 variants of uncertain significance.
Introduction
The limb-girdle muscular dystrophies (LGMDs) comprise a genetically complex group of muscular diseases affecting preferably proximal muscles [1] . The human ANO5 (TMEM16E) gene harbours > 70 recessive mutations causing adult-onset muscle phenotypes such as limb-girdle muscular dystrophy type 2L (LGMD2L; OMIM 611307) and Miyoshi muscular dystrophy-like disease with distal phenotype (MMD3; OMIM 613319) [2] [3] [4] [5] .
Clinical features can vary from just high CK levels, mild weakness and exercise myalgia to more severe muscular atrophies. Weakness can be proximal, distal or both in some cases [3, 4, 6] . Asymmetric muscle involvement and gender imbalance, men being more frequently and more severely affected, are features of anoctaminopathy. No clear genotypephenotype correlation has been found [3, 6] . Dominant mutations in ANO5 affecting the amino acid C356 cause a completely different phenotype: gnathodiaphyseal dysplasia (GDD; OMIM #166260), a skeletal syndrome [7, 8] .
The anoctamin/TMEM16 family of genes, ANO1-ANO10, encodes for 10 eight-pass transmembrane proteins with diverse physiological functions, including Ca 2+ activated Cl À channels, cation channels and lipid scramblases [9] . However, ANO5 does not show any of these activities [10, 11] . A recent report on ANO5-deficient mouse model suggested that ANO5 has a role in muscle membrane repair and regeneration [12] . The human ANO5 gene is transcribed into one protein-coding mRNA species with 22 exons, giving rise to a 913 amino acid, 107 kD ANO5 protein (TMEM16E) (Uniprot Q75V66-1). The functions of ANO5 are not fully clarified, although it may have a role in membrane dynamics [12] . A major restriction for ANO5 research involving human patients has been the lack of specific antibodies. Here, we describe a western blotting method to study ANO5 protein expression in human muscle biopsies and subcellular fractions. The method described here enables analysing the consequences of different ANO5 mutations at protein level.
Materials and Methods

Patients
Biopsies were taken for diagnostic purpose and informed consent was obtained from all individual participants included in the study, according to the Declaration of Helsinki, and approved by the institutional review boards. Altogether eight anoctaminopathy patients (four Finnish, one French and three Italian), homozygous or compound heterozygous for pathogenic ANO5 mutations, were included (Table 1 and Fig. S1 ). One patient with undefined myopathy, heterozygous for one ANO5 anomaly at mRNA level, was used as a carrier control. In addition, 11 control individuals free of muscular disease were included (Table 2) .
Constructs
The plasmid expression vector containing the wild-type full-length human ANO5 cDNA tagged with V5 epitope at its 3 0 end, hANO5wt-V5, has been described previously as hGDD1-V5 [8] .
Cell culture and transfection COS-1 cells (ATCC, Manassas, VA) were cultured at +38°C, 5% CO 2 , in DMEM supplemented with 10% FCS, 1% PenStrep and 1% Glutamax. For transfection experiments, COS-1 cells were seeded on six-well plates and grown to 60-70% confluence overnight. The next day, the cells were transfected with hANO5wt-V5 using FuGene 6 (Promega, Madison, WI), with DNA (lg): FuGene 6 (ll) ratio 1:3. Two days after transfection, the cells were harvested for western blotting. Untransfected COS-1 cells were used as negative control.
Subcellular protein fractionation
Frozen muscle sections (40-60 9 12 lm) were placed in prechilled microcentrifuge tubes, and ProteoExtract Subcellular Proteome Extraction Kit (Calbiochem, Merck KGaA, Darmstadt, Germany) was used to separate soluble, insoluble and membrane protein fractions.
The extraction was performed according to the manufacturer's instructions.
ANO5 western blotting
The membrane protein fractions were placed on ice and sonicated in water bath sonicator 3 9 1 min, cooling on ice in between pulses. Alternatively, RIPA buffer, pH 8.0, supplemented with HALT/EDTA Protease Inhibitor Cocktail (100x) (Thermo Fisher Scientific, Waltham, MA) was added to frozen muscle sections in precooled microcentrifuge tubes, lysed by vortexing for 10 sec, and sonicated as above. Laemmli sample buffer (19) and beta-mercaptoethanol (10%) were added, and the samples were incubated for 10 min at room temperature. Solution was centrifuged for 5 min, 16 000 g, and supernatant was used for SDS-PAGE and western blotting onto PVDF membranes using conventional methods. For COS-1 cells, 220 ll RIPA with protease inhibitors was added to a single well on six-well plate, and the cells were collected in a microcentrifuge tube using a cell scraper. The samples were processed by vortexing and sonication, as described above. PVDF filters were detected using primary ANO5 mAb N421A/85 (UC Davis/NIH NeuroMab, Davis, CA, USA), raised against human ANO5 aa 1-299, at dilution 1:20 in TBST/5% non-fat milk powder solution overnight at +8°, with gentle agitation. Super Signal Femto (Pierce, Thermo Fisher Scientific) substrate at dilution 2:5 (in PBS) was used for ECL reaction, and the signal was detected with ChemiDoc reader (Bio-Rad Laboratories, CA). Appropriate loading controls were used for different samples: myosin heavy chain (MyHC) band, stained with Coomassie Brilliant Blue, for total muscle extracts and insoluble fractions; GAPDH (ab8245, Abcam, Cambridge, UK) for COS-1 cells and muscle soluble fractions; pooled SERCA1/SERCA2 (clone VE121G9, Research Diagnostics Inc., NJ, USA and ab2817, Abcam respectively) or DHPR (ab2862, Abcam) for muscle membrane fractions. V5 antibody (clone SV5-P-k, Invitrogen) was used to detect the V5-tagged constructs.
The ANO5, SERCA(1/2) and DHPR bands were quantitated using the ImageLab v5.0 software (BioRad) to obtain band volumes (integrated densities). Next, the ANO5/SERCA and ANO5/DHPR ratios were calculated 
Results
In transfected COS-1 cells, western blotting revealed a band migrating just above the 100 kD marker, with both V5 and ANO5 N421A/85 antibodies, corresponding with the size of the expressed hANO5wt-V5 construct (109 kD) (Fig. 1A ). An additional > 200 kD band was observed, likely representing ANO5 dimers. Three other ANO5 antibodies, one commercial and two custom-made, were tested as well, but they failed to recognize specifically the ANO5 protein in Western blotting (Fig. S2) .
Next, muscle biopsy sections from normal controls and ANO5 patients were prepared into WB samples. A band of~100 kD was observed in control muscle extracts, whereas this band seemed reduced to some extent in all patients (Fig. 1B) . No truncated ANO5 polypeptides were observed with the N-terminal ANO5 N421A/85 antibody. Several bands of different molecular weights were observed as well, but they were interpreted as unspecific, as they were present in all controls and patients tested. Notably, there were also unspecific bands just above and beneath of the full-length ANO5, making reliable quantitation of specific bands impossible.
In order to study the ANO5 subcellular distribution, and to eliminate unspecific bands, we performed muscle tissue fractionation and analysed the soluble (F1), membranous (F2) and insoluble (F4) fractions in controls and three ANO5 patients. In all controls and in patient Fin3 (c.2272C/c.2272C), a single~100 kD ANO5 band was clearly seen in the membrane fraction F2, but hardly detectable in patients Fin5 (c. 2272C>T/ c.191dupA) and Ita3 (c.191dupA/c.191dupA) (Fig. 1C) . Notably, most unspecific bands were found in the soluble fraction F1.
We then quantitated the ANO5 protein bands in membrane fractions of six controls and seven anoctaminopathy patients ( Fig. 2A) , and determined the relative expression by calculating the ANO5/SERCA and ANO5/DHPR ratios (Fig. 2B) . The results were uniform with both membrane protein markers, showing that ANO5 was clearly decreased in all patients. The c.191dupA homozygous patient Ita3 showed only residual ANO5 expression, as expected; otherwise no clear correlation in expression could be seen with different mutations.
Because of the relatively selective involvement of different muscles in anoctaminopathy, we assessed the ANO5 protein expression level in a set of different control muscles. However, in the muscles tested (gastrocnemius, tibialis anterior, biceps femoris and semimembranosus), there were very small differences in the expression levels between individual specimens, but no marked differences between the different muscle groups (Fig. S3) . A band of~100 kD was consistently seen, and no sign of possible isoform variation.
Immunohistochemistry experiments were not successful in obtaining specific labelling using human muscle biopsies, probably due to too low affinity for the natural conformation of the protein (Fig. S4) .
All the experiments were replicated 2-4 times, giving highly reproducible results.
Discussion
Setting up a reliable method to detect endogenous ANO5 protein has proved to be very challenging. Previous attempts to determine ANO5 expression have been complicated by the high degree of unspecific signals with the ANO5 antibodies used, most of which have not identified the correct protein at all. For example, Xu et al. recently reported that two commercial ANO5 antibodies do not recognize ANO5 protein [13] . Possible reasons for ANO5 resistance for immunological detection may be its low immunogenicity and hydrophobic nature of eight transmembrane domains, making the extraction of ANO5 difficult.
Here, we used an SDS-PAGE sample preparation method, where membrane proteins are gently extracted using detergents and sonication in low temperature. With mAb clone N421A/85, COS-1 cells expressing the construct hANO5wt-V5 showed the correct band of 109 kD, which was absent in untransfected cells. In human total muscle lysates, ã 100 kD band was observed, but also several unspecific bands, some of which very close in size to the ANO5 band. In order to confirm ANO5 membrane localization and monitor if it might change in patients, tissue fractionation was performed. ANO5 was found solely in the membrane fraction in all biopsies studied. No accumulation of ANO5 was seen in the insoluble fraction in any of the patients. By eliminating most unspecific bands, we were able to quantify ANO5 expression in relation to membrane protein markers SERCA(1/2) and DHPR. ANO5 protein was clearly reduced in all anoctaminopathy patients, regardless of the mutation. No truncated ANO5 protein fragments associated with frameshift mutations were detected. The mAb N421A/85 binding site may be located downstream of the c.191dupA mutation in exon 5, common in European population, and detection of such truncated product would therefore be impossible. However, if the nonsense mutation c.1261C>T in exon 13 would produce a truncated protein, it could have been recognized by the antibody. We conclude that these mutations likely cause nonsense-mediated mRNA decay, and loss of ANO5 protein expression. Figure 2A were quantitated, and ANO5/SERCA and ANO5/ DHPR ratios were calculated. Controls (n = 6) were combined, and their average value was normalized to 1 (column 1). The expression of ANO5 in all patient samples (columns 2-8) was clearly decreased, being lowest in Fin5 (c.191dupA/c.2272C>T) and Ita3 (c.191dupA/c.191dupA). The experiment was performed in duplicate, with similar results. ANO5/SERCA, controls: min value = 0.606; max value = 2,021; average = 1,000; STDEV = 0,533; ANO5/SERCA, patients: min value = 0,019; max value: 0,297; average = 0,123; STDEV = 0,096. ANO5/DHPR, controls: min value = 0,661; max value = 1,287; average = 1,000; STDEV = 0,249; ANO/DHPR, patients: min value = 0,016; max value = 0,289; average = 0,135; STDEV = 0,106.
Hence, we show that the correct ANO5 protein is possible to detect with a specific methodology, and that it is expressed in human skeletal muscle as a single major isoform of 107 kD. Relatively sharp appearance of the band suggests no major high molecular weight covalent post-translational modifications, such as glycosylation, which is in agreement with the suggested localization of ANO5 in ER or intracellular membrane vesicles [11, 14, 15] (based mostly on detection of tagged constructs in transfected cells).
In a recent biochemical study, ANO5 was found to be an unstable protein, which undergoes constitutive proteasomal degradation [11] , and the GDD mutation C356R was shown to further decrease ANO5 stability [11] . The myopathy-causing recessive ANO5 mutations are distributed throughout the gene. Based on the results described here, it seems likely that most, if not all mutations destabilize the protein, either by misfolding, compromising its processing in the ER, or affecting its correct incorporation into membranes, leading to more rapid degradation and decreased ANO5 levels. However, it cannot be ruled out that some mutations may primarily affect protein functionality. Different mutations leading to ANO5 instability and degradation could manifest as low genotype-phenotype correlation. Certainly, a wider spectrum of different ANO5 mutations needs to be analysed to see which impact they have at the protein level.
Direct detection of ANO5 by western blotting for diagnostic purposes and for determining pathogenicity of ANO5 mutations is now possible. Particularly, the large number of LGMD patients with both causative and elusive variants in the ANO5 gene would benefit from the protein analysis, making it a suitable second-tier test after an NGS assay. We show that endogenous ANO5 protein is most reliably detected and quantitated using isolated membrane protein fraction. The method described here provides a tool for research and further understanding of the ANO5 function.
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